Lite Strategy, Inc. a clinical-stage pharmaceutical company, focuses on the development of novel and differentiated therapies for the treatment of cancer.
$1.02+4.93%
报价 2026-11-06
市值
$31M
EV
$41.1M
PE (TTM)
–
预期 PE (FY2027)
–
52 周区间距高点 -54.9%
$0.74$2.26
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LITSLite Strategy, Inc. | $31M | +4.9% | 0.0% | 0% | – | – | – | |
| RLMDRelmada Therapeutics, Inc. | $416M | +3.4% | +300.0% | 0% | – | – | – | |
| IMUXImmunic, Inc. | $105.7M | +5.9% | -96.9% | 0% | – | – | – | |
| ACRVAcrivon Therapeutics, Inc. Common Stock | $69M | +2.5% | +1400.0% | 0% | – | – | – | |
| NTRBNutriband Inc. | $67.5M | -0.4% | +3433.3% | 33.1% | – | – | – | |
| PMVPPMV Pharmaceuticals, Inc. | $67.2M | -1.2% | – | 0% | – | – | – | |
| XBITXBiotech Inc. | $57.6M | +1.1% | – | 0% | – | – | – | |
| HOWLWerewolf Therapeutics, Inc. | $49.1M | -1.0% | +232.0% | 86.4% | – | – | – | |
| ACETAdicet Bio, Inc. | $28.6M | +4.5% | 0.0% | 0% | – | – | – | |
| 同行中位数 | – | – | +266.0% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。